(Q33631716)

28 July 2017

1 reference

title

Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection (English)

1 reference

28 July 2017

De Clercq E

1

1 reference

28 July 2017

publication date

1 January 1999

1 reference

28 July 2017

1 reference

28 July 2017

volume

54

1 reference

28 July 2017

issue

1-2

1 reference

28 July 2017

page(s)

26-45

1 reference

Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: strategies to overcome drug resistance development

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

What can be Expected from Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) in the Treatment of Human Immunodeficiency Virus Type 1 (HIV-1) Infections?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

An antiviral target on reverse transcriptase of human immunodeficiency virus type 1 revealed by tetrahydroimidazo-[4,5,1-jk] [1,4]benzodiazepin-2 (1H)-one and -thione derivatives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Inhibition of HIV-1 Replication by a Nonnucleoside Reverse Transcriptase Inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by the dipyridodiazepinone BI-RG-587

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

L-696,229 specifically inhibits human immunodeficiency virus type 1 reverse transcriptase and possesses antiviral activity in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5''-(4''-amino-1'',2''- oxathiole-2'',2'-dioxide)pyrimidine (TSAO) nucleoside analogues: highlyselective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcri

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

[2',5'-Bis-O-(tert-butyldimethylsilyl)]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide) (TSAO) derivatives of purine and pyrimidinenucleosides as potent and selective inhibitors of human immunodeficiency virus type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

The PETT series, a new class of potent nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

New tetrahydroimidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-one and -thione derivatives are potent inhibitors of human immunodeficiency virus type 1 replication and are synergistic with 2',3'-dideoxynucleoside analogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Synthesis and potent anti-HIV-1 activity of novel 6-benzyluracil analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Inhibition of human immunodeficiency virus type 1 wild-type and mutant reverse transcriptases by the phenyl ethyl thiazolyl thiourea derivatives trovirdine and MSC-127.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relationship studies of PETT analogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Activity of various thiocarboxanilide derivatives against wild-type and several mutant human immunodeficiency virus type 1 strains.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Thiazolobenzimidazole: biological and biochemical anti-retroviral activity of a new nonnucleoside reverse transcriptase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Selective non-nucleoside HIV-1 reverse transcriptase inhibitors. New 2,3-dihydrothiazolo[2,3-a]isoindol-5(9bH)-ones and related compounds with anti-HIV-1 activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Viral resistance to the thiazolo-iso-indolinones, a new class of nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

5-chloro-3-(phenylsulfonyl)indole-2-carboxamide: a novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Biological and biochemical anti-HIV activity of the benzothiadiazine class of nonnucleoside reverse transcriptase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Synthesis of a series of 4-(arylethynyl)-6-chloro-4-cyclopropyl-3,4-dihydroquinazolin-2(1H)-ones as novel non-nucleoside HIV-1 reverse transcriptase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum lanigerum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Structural analogues of the calanolide anti-HIV agents. Modification of the trans-10,11-dimethyldihydropyran-12-ol ring (ring C).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Synthesis and anti-HIV-1 activity of a series of imidazo[1,5-b]pyridazines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Potent and specific inhibition of human immunodeficiency virus type 1 replication by 4-(2,6-dichlorophenyl)-1,2,5-thiadiazol-3-Y1 N,N-dialkylcarbamate derivatives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Anti-HIV-1 activity of thiadiazole derivatives: structure-activity relationship, reverse transcriptase inhibition, and lipophilicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

New arylpyrido-diazepine and -thiodiazepine derivatives are potent and highly selective HIV-1 inhibitors targeted at the reverse transcriptase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

A new series of pyridinone derivatives as potent non-nucleoside human immunodeficiency virus type 1 specific reverse transcriptase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Synthesis and anti-HIV-1 activity of a series of 1-alkoxy-5-alkyl-6-(arylthio)uracils

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Novel non-nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. 6. 2-Indol-3-yl- and 2-azaindol-3-yl-dipyridodiazepinones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Pyrrolobenzothiazepinones and pyrrolobenzoxazepinones: novel and specific non-nucleoside HIV-1 reverse transcriptase inhibitors with antiviral activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

The benzylthio-pyrimidine U-31,355, a potent inhibitor of HIV-1 reverse transcriptase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

1,2,5-Benzothiadiazepine and pyrrolo[2,1-d]-[1,2,5]benzothiadiazepine derivatives with specific anti-human immunodeficiency virus type 1 activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Synthesis and biological evaluation of 5H-indolo [3,2-b][1,5]benzothiazepine derivatives, designed as conformationally constrained analogues of the human immunodeficiency virus type 1 reverse transcriptase inhibitor L-737,126.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

(-)-6-Chloro-2-[(1-furo[2, 3-c]pyridin-5-ylethyl)thio]-4-pyrimidinamine, PNU-142721, a new broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Novel 1,1,3-trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine derivatives as non-nucleoside reverse transcriptase inhibitors that inhibit human immunodeficiency virus type 1 replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Synthesis and anti-HIV activity of novel N-1 side chain-modified analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

High resolution structures of HIV-1 RT from four RT-inhibitor complexes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor alpha-APA R 95845 at 2.8 A resolution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Molecular modeling studies of HIV-1 reverse transcriptase nonnucleoside inhibitors: total energy of complexation as a predictor of drug placement and activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

A proline-to-histidine substitution at position 225 of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) sensitizes HIV-1 RT to BHAP U-90152.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Models which explain the inhibition of reverse transcriptase by HIV-1-specific (thio)carboxanilide derivatives.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

An extensively modified version of MolScript that includes greatly enhanced coloring capabilities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Mutational analysis of residue 190 of human immunodeficiency virus type 1 reverse transcriptase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

In vitro selection for different mutational patterns in the HIV-1 reverse transcriptase using high and low selective pressure of the nonnucleoside reverse transcriptase inhibitor HBY 097.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Subunit specificity of mutations that confer resistance to nonnucleoside inhibitors in human immunodeficiency virus type 1 reverse transcriptase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Resistance to 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives is generated by mutations at multiple sites in the HIV-1 reverse transcriptase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Differential activities of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives against different human immunodeficiency virus type 1 mutant strains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Suppression of the breakthrough of human immunodeficiency virus type 1 (HIV-1) in cell culture by thiocarboxanilide derivatives when used individually or in combination with other HIV-1-specific inhibitors (i.e., TSAO derivatives)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

A novel mutation (F227L) arises in the reverse transcriptase of human immunodeficiency virus type 1 on dose-escalating treatment of HIV type 1-infected cell cultures with the nonnucleoside reverse transcriptase inhibitor thiocarboxanilide UC-781.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Susceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reserve transcriptase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Zidovudine-resistant human immunodeficiency virus type 1 strains subcultured in the presence of both lamivudine and quinoxaline HBY 097 retain marked sensitivity to HBY 097 but not to lamivudine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Retention of marked sensitivity to (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-di hydroquin oxaline-2(1H)-thione (HBY 097) by an azidothymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the com

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Concomitant combination therapy for HIV infection preferable over sequential therapy with 3TC and non-nucleoside reverse transcriptase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3'-azido-3'-deoxythymidine or 2',3'-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor MKC-442, alone and in combination with other anti-HIV compounds

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

In vitro inhibition of human immunodeficiency virus type 1 by a combination of delavirdine (U-90152) with protease inhibitor U-75875 or interferon-alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Synergistic inhibition of human immunodeficiency virus type 1 (HIV-1) replication in vitro by 1-[(2-hydroxyethoxy)methyl]-6-phenylthiothymine (HEPT) and recombinant alpha interferon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Complete inhibition of viral breakthrough by combination of MKC-442 with AZT during a long-term culture of HIV-1 infected cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Combination therapy with zidovudine prevents selection of human immunodeficiency virus type 1 variants expressing high-level resistance to L-697,661, a nonnucleoside reverse transcriptase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Phase 1 study of combination therapy with L-697,661 and zidovudine. The ACTG 184 Protocol Team

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients. The Dutch-Italian-Australian Nevirapine Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group P

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Knocking-out concentrations of HIV-1-specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drug-resistant virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Prevention of the spread of HIV-1 infection with nonnucleoside reverse transcriptase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Selection conditions affect the evolution of specific mutations in the reverse transcriptase gene associated with resistance to DMP 266.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Prophylaxis against HIV-1 infection in chimpanzees by nevirapine, a nonnucleoside inhibitor of reverse transcriptase.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Pharmacokinetics of R 82913 in patients with AIDS or AIDS-related complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Pharmacokinetics of R 82913 in AIDS patients: a phase I dose-finding study of oral administration compared with intravenous infusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Plasma viremia as a sensitive indicator of the antiretroviral activity of L-697,661.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. L-697,661 Working Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Second-generation non-nucleosidic reverse transcriptase inhibitor HBY097 and HIV-1 viral load

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

A Pilot Study to Evaluate the Development of Resistance to Nevirapine in Asymptomatic Human Immunodeficiency Virus-Infected Patients with CD4 Cell Counts of >500/mm3 : AIDS Clinical Trials Group Protocol 208

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Viral dynamics of HIV: implications for drug development and therapeutic strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Viral dynamics in human immunodeficiency virus type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Studies in subjects with long-term nonprogressive human immunodeficiency virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

HIV viral load markers in clinical practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Prognosis in HIV-1 infection predicted by the quantity of virus in plasma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Serum levels of human immunodeficiency virus type 1 (HIV-1) RNA after seroconversion: a predictor of long-term mortality in HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Recovery of replication-competent HIV despite prolonged suppression of plasma viremia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

Resistance pattern of human immunodeficiency virus type 1 reverse transcriptase to quinoxaline S-2720

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2898%2900103-7

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0014-827X(98)00103-7

1 reference

release_yjbqesosyjhnlgotkmiymyyvjy

28 July 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/yjbqesosyjhnlgotkmiymyyvjy

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference